Ascribe Bio, an innovator in natural crop protection, today announced the closing of an oversubscribed $12 million Series A financing round. This milestone advances Ascribe’s small-molecule technology platform and supports the upcoming commercial launch of Phytalix. Phytalix is a revolutionary ‘biofungicide without compromise’ that provides the health and sustainability benefits of biologicals with the ease of use and affordability of traditional chemical crop protection products…
